Company

Location

Amt. (M)

Round

Details

Date

TOTAL: $924.44M

Adynxx Inc.

San Francisco

$16

Series B

$16M led by new investor TPG Biotech, with participation from existing investor Domain Associates

1/11/17

Ascentage Pharma Group

Taizhou, China

$72

Series B

¥500M (US$72M) from Future Industry Investment Fund, Shiyu Capital, Hidragon Capital and Founder KIP Capital, along with previous investors Yuanming Capital, Oriza Venture Fund and Efung Capital

1/4/17

Ascletis Pharmaceuticals Co. Ltd.

Hangzhou and Shaoxing, China

$100

Series B

$100M from China-based venture capital firms

1/4/17

Avidity Biosciences Inc.

La Jolla, Calif.

$16

Series B

$16M including $10M investment and conversion of $6M in convertible debt; Takeda Pharmaceuticals Ltd.'s venture group led, with Alethea Capital, Alexandria Real Estate Equities, Brace Pharma, Ecor1 Capital, F-Prime Capital, Moore Venture Partners and Tavistock Life Sciences participating

1/6/17

Biscayne Neurotherapeutics Inc.

Miami

$3

Series B

$3M led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners

1/30/17

Blackthorn Therapeutics Inc.

South San Francisco

$14

Series A

$14M extension from GV (formerly Google Ventures) and Biomatics Capital), bringing total to $54M; $40M closed October 2016

1/6/17

Cavion Inc.

Charlottesville, Va.

$26.1

N/A

$26.1M co-led by Lilly Ventures and Novartis Venture Fund, in tandem with Enso Ventures and existing investors

1/9/17

Cellestia Biotech AG

Basel, Switzerland

$8

Seed

CHF8M (US$8M) with CHF500,000 from seed A and CHF2.3M from seed B rounds in 2016 along with a seed C round that closed Thursday at CHF5.2M; PPF Group, as an institutional investor, and undisclosed private investors participated in the C round

1/27/17

Corbin Therapeutics

Montreal

$0.76

Seed

C$1M (US$756,162) seed money as it spins out from Amorchem Holdings Inc.

1/10/17

Cristal Therapeutics BV

Maastricht, the Netherlands

$13.7

N/A

€12.8M (US$13.7M) from Biogeneration Ventures and new investors Aglaia Biomedical Ventures and Belgian oncology investor Droia

1/20/17

Cue Biopharma Inc.

Cambridge, Mass.

$16.4

N/A

$16.4M round, added to $10M seed funding; MDB Capital Group served as lead investor

1/25/17

Desentum Oy

Espoo, Finland

$2.5

Series A

€2M (US$2.5M) in a series A

1/24/17

Endoceutics Inc.

Quebec City

$85

N/A

$85M senior credit facility with CRG LP (Capital Royalty LP)

1/13/17

Eternygen GmbH

Berlin

$8.3

N/A

€8M (US$8.3M) round from Evotec AG and Epidarax Capital, VC Fonds Technologie Berlin and two family offices

1/10/17

Fibrocor Therapeutics LP

Toronto

$2.1

N/A

C$2.8M (US$2.1M) from Evotec AG, of Hamburg, Germany, and MaRS Innovation, of Toronto

1/18/17

Heparegenix GmbH

Germany

$9.4

Series A-1

€9M (US$9.4M) from Boehringer Ingelheim Venture Fund and Novo Seeds High-Tech Grunderfonds also contributed

1/6/17

Jupiter Orphan Therapeutics Inc.

Jupiter, Fla.

$1

N/A

$2M from Tarnagulla Ventures, of Melbourne, Australia; convertible note with $1M paid out immediately and $1M tied to milestones

1/6/17

Kiniksa Pharmaceuticals

Bermuda and Boston

$80

Series A

$80M, closed in 2016 but announced in 2017 at J.P. Morgan, led an undisclosed investor group, with company management participating

1/13/17

Macrophage Pharma Ltd.

Windsor, U.K.

$10.9

Series A

£9M (US$10.9M) led by the Cancer Research U.K. Technology Pioneer Fund, and joined by Novo Seeds and Dutch VC Aglaia Biomedical Ventures

1/10/17

Maverick Therapeutics Inc.

Brisbane, Calif.

$23

Series B

$23M from MPM Capital's Bioventures 2014, the UBS Oncology Impact Fund and Takeda Pharmaceutical Co. Ltd.

1/12/17

Microbion Corp.

Bozeman, Mont.

$25

N/A

$25M investment from Quark Ventures Inc. and GF Securities

1/6/17

Napo Pharmaceuticals Inc.

San Francisco

$2

N/A

$2M in secured convertible debt financing from Kingdon Capital Management LLC, of New York

1/4/17

Neon Therapeutics Inc.

Cambridge, Mass.

$70

Series B

$70M led by Partner Fund Management, with Third Rock Ventures, Access Industries, and additional new investors Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures and Nextech Invest

1/5/17

Nerre Therapeutics Ltd.

Stevange, U.K.

$28.2

Series B

£23M (US$28.2M) led by Fountain Healthcare Partners, along with new investors Forbion Capital Partners, and Orbimed Advisors LLC; existing investors Advent Life Sciences and Novo A/S also participated

1/5/17

Neurelis Inc.

San Diego

N/A

Series B

Led by HBM Healthcare Investments, with participation from Lyzz Capital

1/6/17

Octimet Oncology NV (spinout of Janssen Pharmaceutica NV)

Beerse, Belgium

$12

Series A

€11.3M (US$12M) in a series A round led by V-Bio Ventures and Fund+, two Belgian funds, with additional participation from Droia Oncology Ventures (Luxembourg and Belgium) and Omnes Capital (France)

1/20/17

Oncoimmune Inc.

Rockville, Md.

$15

Series A

$15M round led by 3E Bioventures Capital

1/13/17

Phasebio Pharmaceuticals Inc.

Malvern, Pa.

$14.7

N/A

$14.7M in convertible notes from New Enterprise Associates, Astrazeneca plc, Johnson & Johnson Innovation-JJDC, Hatteras Venture Partners, Fletcher Spaght Ventures and Syno Capital

1/19/17

Pionyr Immunotherapeutics Inc.

San Francisco

$8

Series A-1

$8M led by Orbimed and SV Life Sciences, with Osage University Partners, Mission Bay Ventures and private angel investors

1/5/17

Satsuma Pharmaceuticals Inc.

San Francisco

$12

Series A

$12M co-led by RA Capital Management and TPG Biotech

1/6/17

SCPharmaceuticals Inc.

Lexington, Mass.

$45.6

Series B

$45.6M co-led by Orbimed and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd., and existing investors 5AM Ventures and Lundbeckfond Ventures

1/5/17

Semathera

Montreal

$0.76

Seed

C$1M (US$758,748) from Amorchem Holdings Inc., which spun out Semathera

1/12/17

Siteone Therapeutics Inc.

Bozeman, Mont.

$15

Series B

$15M round led by Amgen Inc. and joined by founding investors Next Frontier Capital, 2M Companies Inc., Mission Bay Capital, Sears Capital Management, Biobrit LLC and Z Investments

1/9/17

TC Biopharm Ltd.

Edinburgh, Scotland

$7.82

Series A

£6.25M (US$7.82M) from Nipro Corp., of Osaka, Japan, and the Scottish Investment Bank, augmented by several family-based investment sources

1/31/17

Therachon AG

Basel, Switzerland

$5

Series A

$5M final close, bringing total to $40M; $35M was received in September 2015

1/6/17

Trefoil Therapeutics Inc.

San Diego

$5.2

Series 1

$5.2M led by Hatteras Venture Partners and including AJU IB Investment, Correlation Ventures, Exsight Capital and Infocus Capital

1/6/17

Vir Biotechnology Inc.

San Francisco

$150

N/A

$150M investment from Arch Venture Partners and other sovereign wealth funds, public mutual funds and prominent individuals and family offices, plus additional funds from the Bill & Melinda Gates Foundation

1/9/17


Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.